Rajesh Kumar

Rajesh Kumar Analyst Performance

Senior Global Healthcare Analyst | Team Head at HSBC

Rajesh Kumar is a stock analyst at HSBC in the healthcare sector, covering 19 publicly traded companies. Over the past year, Rajesh Kumar has issued 25 stock ratings, including buy, hold, and sell recommendations. While full access to Rajesh Kumar's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Rajesh Kumar's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
43 Last 2 Years
Buy Recommendations
51.22% 21 Buy Ratings
Companies Covered
19 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy14.6%6 ratings
Buy36.6%15 ratings
Hold29.3%12 ratings
Sell19.5%8 ratings

Out of 41 total stock ratings issued by Rajesh Kumar at HSBC, the majority (36.6%) have been Buy recommendations, followed by 29.3% Hold, 19.5% Sell, and 14.6% Strong Buy.

Exchange Coverage

ExchangePercentageCount
NYSE
63.2% of companies on NYSE
12 companies
NASDAQ
26.3% of companies on NASDAQ
5 companies
OTCMKTS
10.5% of companies on OTCMKTS
2 companies

Rajesh Kumar, an analyst at HSBC, currently covers 19 companies listed on NYSE, NASDAQ and OTCMKTS, with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Healthcare
19 companies
100.0%

Rajesh Kumar of HSBC specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
PHARMACEUTICALS
12 companies
63.2%
BIOTECHNOLOGY
5 companies
26.3%
LIFE SCIENCES TOOLS & SERVICES
2 companies
10.5%

Rajesh Kumar's Ratings History at HSBC

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Pfizer Inc. stock logo
PFE
Pfizer
9/10/2026Boost Price Target$27.82$30.00Hold
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
9/10/2026Boost Price Target$1,123.42$940.00Reduce
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
9/10/2026Reiterated Rating$64.46$65.00Hold
AbbVie Inc. stock logo
ABBV
AbbVie
9/10/2026Boost Price Target$251.04$315.00Buy
Novartis AG stock logo
NVS
Novartis
9/10/2026Upgrade$137.52$136.00Hold
Novartis AG stock logo
NVS
Novartis
9/10/2026Upgrade$137.52$136.00Hold
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
9/10/2026Boost Price Target$146.68$172.00Buy
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
9/10/2026Boost Price Target$803.35$920.00Buy
Zoetis Inc. stock logo
ZTS
Zoetis
7/6/2026Lower Price Target$75.29$95.00Buy
Biogen Inc. stock logo
BIIB
Biogen
7/6/2026Reiterated Rating$212.49$157.00Reduce
Pfizer Inc. stock logo
PFE
Pfizer
7/6/2026Downgrade$24.29$28.00Hold
Gilead Sciences, Inc. stock logo
GILD
Gilead Sciences
7/6/2026Upgrade$131.27$155.00Buy
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7/6/2026Lower Price Target$650.11$880.00Buy
Danaher Corporation stock logo
DHR
Danaher
6/3/2026Lower Price Target$175.97$230.00Buy
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
3/17/2026Downgrade$987.83$850.00Reduce
Biogen Inc. stock logo
BIIB
Biogen
3/17/2026Boost Price Target$183.26$150.00Reduce
Pfizer Inc. stock logo
PFE
Pfizer
3/17/2026Boost Price Target$27.11$32.00Buy
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
3/17/2026Boost Price Target$60.55$60.00Hold
Roche Holding AG stock logo
RHHBY
Roche
12/10/2025Reiterated Rating$48.70$57.00Buy
Pfizer Inc. stock logo
PFE
Pfizer
12/10/2025Reiterated Rating$25.36$29.00Buy
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
12/10/2025Reiterated Rating$46.32$54.00Hold
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
12/10/2025Reiterated Rating$981.89$1,070.00Hold
Biogen Inc. stock logo
BIIB
Biogen
12/10/2025Reiterated Rating$175.84$143.00Reduce
AbbVie Inc. stock logo
ABBV
AbbVie
12/10/2025Upgrade$222.83$265.00Buy
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11/24/2025Downgrade$44.40Hold
IQVIA Holdings Inc. stock logo
IQV
IQVIA
10/9/2025Upgrade$200.60$235.00Buy
AbbVie Inc. stock logo
ABBV
AbbVie
10/2/2025Set Price Target$244.77$225.00
Roche Holding AG stock logo
RHHBY
Roche
10/2/2025Upgrade$44.83$50.00Buy
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
10/1/2025Set Price Target$59.15$70.00Buy
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
10/1/2025Upgrade$58.57$70.00Buy
AbbVie Inc. stock logo
ABBV
AbbVie
10/1/2025Downgrade$239.82Hold
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
10/1/2025Boost Price Target$840.46$800.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
8/27/2025Upgrade$734.93$700.00Hold
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
6/11/2025Upgrade$8.03Strong-Buy
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4/28/2025Downgrade$884.94$700.00Reduce
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4/28/2025Downgrade$877.25Moderate Sell
Bayer Aktiengesellschaft stock logo
BAYRY
Bayer Aktiengesellschaft
4/28/2025Upgrade$6.59Hold
GSK PLC Sponsored ADR stock logo
GSK
GSK
4/28/2025Upgrade$39.83Strong Sell
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
4/28/2025Upgrade$66.53Strong-Buy
Sanofi stock logo
SNY
Sanofi
4/28/2025Upgrade$54.95Strong-Buy
Your book is inside (Ad)

The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel

Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
4/28/2025Upgrade$15.51Strong-Buy
Pfizer Inc. stock logo
PFE
Pfizer
3/10/2025Upgrade$25.73Strong-Buy